AVECTAS Leads €7.23 million Consortium Awarded Part Funding From Ireland’s Disruptive Technologies Innovation Fund
Funding to develop high throughput cell engineering technology to manufacture off the shelf cell therapies
Project, led by Avectas in partnership with Bluebridge Technologies and National Institute for Bioprocessing Research and Training (NIBRT), would support Ireland s goal of being at the forefront of cell therapy manufacturing
Kildare, Ireland and Cambridge, MA, USA … Friday 23 April 2021. Irish cell engineering company, Avectas, is leading a consortium which will invest €7.23 million, including €4.4 million awarded under the Irish Government’s Disruptive Technology Innovation Fund (DTIF), to develop a high-throughput scale of its proprietary cell engineering platform Solupore®. With consortium partners Bluebridge Technologies and NIBRT, the project expands Avectas development towards commercialising an advanced large-scale, digitalised cell engin
Share this article
Share this article
DUBLIN, April 22, 2021 /PRNewswire/ Irish cell engineering company, Avectas, is leading a consortium which will invest €7.23 million, including €4.4 million awarded under the Irish Government s Disruptive Technology Innovation Fund (DTIF), to develop a high-throughput scale of its proprietary cell engineering platform Solupore®. With consortium partners Bluebridge Technologies and NIBRT, the project expands Avectas development towards commercialising an advanced large-scale, digitalised cell engineering platform optimised to manufacture off-the-shelf cell-based therapies for cancer treatment.
The Disruptive Technologies Innovation Fund (DTIF) is a €500 million fund established under Project Ireland 2040 and run by the Department of Enterprise Trade and Employment with support from Enterprise Ireland.